N-acetylcysteine and raloxifene boost photodynamic therapy against cutaneous squamous cell carcinoma by decreasing TGFβ1 secreted by cancer-associated fibroblasts. The gene discussed is TGFB1; the disease is cutaneous squamous cell carcinoma.